Pulmonary ionocytes, a rare airway cell type that produces high levels of CFTR — the protein that’s defective in…
Articles by Steve Bryson, PhD
The European Commission (EC) has expanded the approval of Kalydeco (ivacaftor) for the treatment of infants with cystic…
A grant of $500,000 in Australian dollars (around $326,000) will support researchers there in the development of antibiotics formulated with…
Elevated levels of the pro-inflammatory signaling protein galectin-3 in the bloodstream of children with clinically stable cystic fibrosis (CF)…
A protein secreted into the airways, called SPLUNC1, may be a sensitive biomarker of both mild pulmonary exacerbations and treatment…
Children with cystic fibrosis (CF) who began taking Orkambi (lumacaftor/ivacaftor) between ages 2 and 5 showed improved height,…
Zinc may be key to reducing bacterial infections in people with cystic fibrosis (CF), researchers at the University of…
A European Medicines Agency (EMA) committee recommends extending the label for Kalydeco (ivacaftor) to children with cystic fibrosis…
A pooled analysis of data from multiple clinical trials of more than 1,100 people with cystic…
The first volunteer has been dosed in a Phase 1 clinical trial evaluating SION-109, an experimental oral treatment for cystic…